RecruitingPhase 3NCT06473701

Reducing Breathlessness With Dronabinol in COPD Patients

BONG: Reducing Severe Breathlessness With Dronabinol in the Severe and Very Severe Chronic Obstructive Pulmonary Disease Patient Group - A Randomized, Double-Blind, Placebo-Controlled, Crossover Study


Sponsor

Vejle Hospital

Enrollment

30 participants

Start Date

Feb 26, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This clinical trial examines whether Dronabinol, which contains the synthetic psychoactive compound tetrahydrocannabinol (THC), can alleviate severe breathlessness in patients with severe and very severe chronic obstructive pulmonary disease (COPD).


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether dronabinol — a medication derived from cannabis — can help reduce severe breathlessness in people with advanced COPD (a serious lung disease) when standard treatments are no longer working well enough. Breathlessness is one of the most distressing symptoms for people with advanced COPD. **You may be eligible if...** - You have COPD classified as severe or very severe (GOLD stage 3 or 4) - Your breathlessness is severe even with the best available treatment - You are 18 years old or older - You understand and speak Danish - You are able to use effective contraception if you could become pregnant **You may NOT be eligible if...** - You have an active infection or COPD flare-up in the last month - You have been regularly using THC or CBD in the last month - Your life expectancy is less than 3 months - You are taking certain medications that interact with this drug (strong CYP3A4 inhibitors/inducers) - You have a current substance abuse problem - You have a significant psychiatric condition that increases risk Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDronabinol 2.5mg Capsule

Dronabinol 2.5 mg pr capsule. Titration up till 20 mg daily dose.

DRUGPlacebo

Dronabinol-matched placebo capsule containing no active substance.


Locations(1)

Vejle Hospital - A part of Lillebaelt Hospital

Vejle, Region Syddanmark, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06473701


Related Trials